Please provide your email address to receive an email when new articles are posted on . Nonarteritic anterior ischemic optic neuropathy risk was 2.33 times higher with semaglutide. Clinicians need to ...

Plaintiff Todd Engel pictured with his wife and daughter. A Maryland man who has lost his vision due to non-arteritic anterior ischaemic optic neuropathy (NAION) is suing Novo Nordisk, alleging that ...

RA tirzepatide for type 2 diabetes mellitus (T2DM) therapy has lower odds of instigating retinal complications.

GLP-1 RAs are linked to an increased risk of NAION in type 2 diabetes patients, with semaglutide and liraglutide showing significant associations. The study involved over 3.8 million Medicare patients ...

People taking Ozempic and Wegovy may be at increased risk of developing a debilitating eye condition that can cause irreversible vision loss, a study published Wednesday in JAMA Ophthalmology finds.

“Ischemia” is the term doctors use when a part of the body stops getting enough oxygen as a result of restricted blood flow. This is because blood carries oxygen in the body. In the case of NAION, ...

Ozempic blindness isn’t a real diagnosis. It’s a nickname used to describe sudden vision loss that may be linked to the weight loss drugs semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, ...

Nonarteritic anterior ischemic optic neuropathy (NAION) is significantly associated with persistently elevated risk for stroke, independent of typical cardiovascular risk factors, a large ...

In response to a small number of postmarketing reports of vision loss in men taking type 5 phosphodiesterase (PDE-5) inhibitors, the US Food and Drug Administration (FDA) has issued a news release to ...